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Feasibility of Multi-Week PET Studies with a Single 
Injection of 89Zr-phosphate on a Clinical PET/MRI
J. D. Thiessen1,2, J. Sykes1, L. Keenliside1, H. Biernaski1, J. Butler1, 
N. Cockburn1, D. E. Goldhawk1,2, R. T. Thompson1,2, F. S. Prato1,2; 
1Lawson Health Research Institute, London, ON, CANADA, 2Western 
University, London, ON, CANADA.
Aim: 89Zr-labelled p-isothiocyanato-desferrioxamine (89Zr-
DBN) is a promising new cell labeling agent that has the po-
tential to label and track a variety of cells over multiple days 
(Bansal et al. EJNMMI Res (2015) 5:19). In order to better under-
stand the inflammatory process after myocardial infarction, we 
are developing methods to track 89Zr-DBN labeled monocytes 
over multiple weeks. The aim of this study was to assess the 
feasibility of multi-week 89Zr studies on a clinical PET/MRI using 
a single injection of 89Zr-phosphate, measuring the uptake and 
longevity of the tracer in target organs. Subject & Methods: 
A 24.5 kg bred-for-research hound was injected intravenously 
with 80 MBq of 89Zr-phosphate (3D Imaging LLC). Whole-body 
PET/MRI (Siemens Biograph mMR) was acquired under anes-
thetic at 3 hours and 4, 8, 12, and 16 days after injection. Acqui-
sitions consisted of 5-6 bed positions (20 cm each), with 15-30 
minutes/bed position. After 20 days, a head and neck PET/MRI 
acquisition (45 minutes/bed position) preceded measurement 
with a whole body shadow shield gamma detector. Regions of 
interest included whole-body, lungs, liver, kidneys and bone 
(vertebrae, sacrum, sternum, ribs, scapula) and were defined 
using a threshold in the PET image with additional reference to 
anatomy in the MRI (3D Slicer). All experiments were approved 
by the local animal care committee. Results: At 3 hours, 97% 
of the injected dose (ID) was measured in the whole-body 
scan, with activity concentrated in the lungs, liver, and blood. 
Whole-body activity decreased to 73% ID by day 4 and stayed 
relatively stable thereafter: (71 ± 2)% ID when averaged over 
days 8-16. Uptake in different regions was also stable by day 
8, with SUV = 3.3 ± 0.2 (liver), 3.  ± 0.3 (lungs), and 10.6 ± 1.5 
(bone) wh n averaged over days 8-16. After 20 days, whole-
body activity was approximately 1 MBq, yet bones in the head 
and neck were still clearly visible. Conclusion: Longitudinal 
studies with 89Zr benefit from a long half-life (78.4 hour ) but 
are limited by low r injected dose and less PET-visible activ-
ity. With its increased sensitivity and additional anatomical 
information, the mMR is well-suited to long-term 89Zr studies. 
With a branching rati  of 0.2275, 1 MBq 89Zr is equivalent to a 
PET sc n f 0.24 MBq 18F. Despite this ultra-low dose, we were 
still able to delineate bones in the head and neck at day 20, 
demonstrating the feasibility of multi-week PET studies using 
89Zr-l belled c lls.
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Introduction: Hybrid or multimodal imaging has provided 
excellent opportunities to meet the needs inherent in the 
management of neurodegenerative diseases, especially in 
Alzheimer Disease (AD) context. Recent PET/MRI equipment 
for simultaneous data acquisition attempts to address this 
challenge. The aim of this review was to compile the main 
advantages related with PET/MRI along with the detection 
of the main challenges which remain to be resolved for a full 
clinical validation of the technique in Neuroimaging field are 
identified. Methods: A literature review was performed, fol-
lowing a PICO methodogy with the question: “What is the role 
of PET/MRI technique in the diagnosis of neurodegenerative 
diseases, specifically in context of Alzheimer’s disease?”. Based 
on the formulated question, keywords and key phrases were 
identified for scientific database research: “Alzheimer”, “neuro-
degenerative disease” “brain” and “PET/MRI” (disambiguation 
terms applied). The SCOPUS platform was used as digital repos-
itory of research. Only “article review” publications since 2010 
in English language were considered. Articles feasibility was 
verified based on exclusion criteria: access to full version pub-
lications, verification of redundant items and empirical analysis 
of abstracts based on their relevance to the research question. 
Results: Based on the methodology and the inclusion criteria 
used, a total of 60 publications were initially obtained, which 
after applying the exclusion criteria dropped to a final number 
of 41 scientific publications. The results obtained were stratified 
into five categories: PET/MRI Equipments - Design and Com-
ponents, Attenuation Correction in PET/MRI, image data re-
construction, PET/MRI in Clinical Neuroimaging, PET/MRI exam 
Protocols. Discussion and Conclusion: AD has been extreme-
ly influenced by the results and imaging capabilities achieved 
by neuroimaging techniques. PET/CT has been successfully ap-
plied in clinical practice with superior results to dedicated PET 
or CT options. However, the ability of MRI to obtain higher spa-
tial resolution levels especially in soft tissues (especially critical 
factor in the context of the brain region) as well as the non-use 
of radiation made evident the need to include this technique 
as a new component to be included in a multimodality solu-
tion. PET/MRI bridge the limitations of PET/CT at the brain level 
and improving the r sults a hieved through a simultaneous re-
al-time combination of quantitative neurophysiological infor-
mation from PET and accurate MRI morphological information, 
with greater radiological safety. PET/MRI technique presents 
high pote tial for diagnostic and follow-up s udies. De pite 
the advantages, sever l hallenges arise and PET/MRI adoption 
in AD imaging still need technical and clinical validation of its 
promising imaging characteristics.
EP-0182
Effect of attenuation and its correction in brain PET/MR 
imaging: a phantom study
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